Berberine HCl — Supplements
Plant-derived alkaloid with meta-analysis-level evidence for blood glucose reduction, lipid lowering, and insulin sensitization — compared to metformin in multiple RCTs.
Overview
Berberine is a quaternary ammonium alkaloid found in Berberis aristata, Coptis chinensis, and related plants. It is one of the most extensively studied botanical compounds for metabolic disease. A 2024 meta-analysis of 50 RCTs (4,150 participants) in Type 2 Diabetes confirmed: fasting plasma glucose −0.59 mmol/L, 2-hour postprandial glucose −1.57 mmol/L, HbA1c −0.69% (when combined with standard care), LDL-C −0.30 mmol/L, and triglycerides −0.35 mmol/L. A separate 2024 meta-analysis of 12 RCTs in metabolic syndrome confirmed reductions in waist circumference (−3.27 cm), triglycerides (−0.37 mmol/L), LDL-C (−0.50 mmol/L), and fasting glucose (−0.52 mmol/L). Head-to-head trials against metformin demonstrate comparable HbA1c reduction with the added benefit of lipid improvement. Berberine is increasingly used in functional medicine for prediabetes, PCOS, metabolic syndrome, and NAFLD/MASLD. Its primary mechanism is AMPK activation (adenosine monophosphate-activated protein kinase), the same pathway targeted by metformin.
Indications
- Prediabetes and blood glucose management
- Type 2 diabetes mellitus (adjunctive therapy)
- Metabolic syndrome (dyslipidemia, central obesity, insulin resistance)
- Polycystic ovary syndrome (PCOS) — insulin-mediated androgen excess
- Non-alcoholic fatty liver disease / MASLD (adjunctive)
Mechanism of Action
Berberine activates adenosine monophosphate-activated protein kinase (AMPK) — the master metabolic sensor — via inhibition of Complex I of the mitochondrial electron transport chain, mimicking the metabolic state of exercise and caloric restriction
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Berberine HCl (≥97% purity) | 500 mg | Three times daily with meals | Most studied protocol; divide across meals to reduce GI AEs and maintain stable plasma levels |
| Berberine HCl (low-dose) | 500 mg | Twice daily with meals | Starting dose for GI-sensitive patients; may have superior lipid effects at lower doses per 2024 meta-analysis |
Safety & Contraindications
- Most common AEs: transient GI effects (constipation, diarrhea, nausea, abdominal discomfort) in ~30-35% — take with meals to minimize
- Significant drug interactions: inhibits CYP3A4 and CYP2D6; can elevate levels of cyclosporine, tacrolimus, statins, and many drugs — full medication review required
- Additive hypoglycemia risk when combined with insulin, sulfonylureas, or GLP-1 agonists — monitor glucose closely
- Avoid in pregnancy — embryotoxic in animal models; berberine crosses the placenta
- Avoid in breastfeeding — excreted in breast milk
- P-glycoprotein inhibitor — can affect absorption of digoxin and other P-gp substrates
- Theoretical risk of jaundice in neonates (bilirubin displacement) — do not use in mothers of G6PD-deficient infants